• FDA Approves Second Biosimilar in Ophthalmology


    Coherus Biosciences announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved Cimerli (ranibizumab-eqrn) as an interchangeable biosimilar product to Lucentis (ranibizumab injection).